logo
  

CTI BioPharma: FDA Extends Review Period For Pacritinib For Treatment Of Myelofibrosis; Stock Down

CTI BioPharma Corp. (CTIC) said that the U.S. Food and Drug Administration has extended the review period for the New Drug Application or NDA for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis or MF with a baseline platelet count of <50 × 109/L.

The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022.

CTIC closed Tuesday regular trading at $2.25 down $0.41 or 15.41%. In the after-hours, the stock further dropped $0.42 or 18.67%.

The FDA had granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021.

In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021.

Earlier today, the FDA informed the company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
RELATED NEWS
Follow RTT